CA-VAULTREE
15.3.2023 14:03:33 CET | Business Wire | Press release
More than 4,100 publicly disclosed data breaches occurred in 2022, with approximately 22 billion records leaked. Most of it was not encrypted. Vaultree, the Data-In-Use Encryption leader, today announced the general availability of a first-of-its-kind software development kit (SDK) to address this massive need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005361/en/
Vaultree's first-of-its-kind Fully Functional Data-In-Use Encryption toolkit will transform enterprise security. (Graphic: Business Wire)
Made possible by a series of major cryptographic breakthroughs by the Vaultree team, the SDK is a user-friendly, simple-to-integrate, and easy-to-use fully scalable solution that enables organizations to benefit from Fully Functional Data-In-Use Encryption, allowing for the processing of fully encrypted data without server-side decryption and complex intermediaries or noticeable delays in data processing.
Vaultree developed the solution to address the problems associated with processing completely encrypted data at scale, ensuring that companies no longer need to sacrifice security for performance and are able to keep their data safe at all times with unmatched simplicity and exceptional encrypted data processing rates. Businesses can retain their tech stack, database, code and SQL syntax, follow the rules, and operate without any perceptible changes, with the added benefit of being completely encrypted and at scale. Vaultree's SDK provides protection, including adherence, security and effectiveness. So, in the event of a leak, rather than issuing an apology about the wholesale exposure of sensitive data, companies will be able to inform clients that although their data has been compromised, it is encrypted, meaning it is protected by encryption, an unparalleled level of security.
This layer of protection also makes CISOs' lives easier by solving one of the most difficult challenges in cybersecurity: persistent data encryption, even in the event of a leak, with the world's first Fully Functional Data-In-Use Encryption solution. Encryption technologies to date have not been able to process encrypted data, decrypting it to plain text for processing and therefore impacting organizations' overall data security, making their data readily available to cyber criminals. Vaultree's encryption solution is smarter, quicker, easier, and more efficient than anything else on the market. Truly zero-trust, it allows users to work with fully encrypted data without key disclosure or server-side decryption. Data-In-Use Encryption maintains data encrypted at all times, even during processing. As an added benefit, there are no intermediaries, which translates to zero learning curve or implementation overhead, making adoption seamless.
Ease of integration and use is another critical differentiator of Vaultree's SDK encryption solution. There is no need to be a cryptographer, no intermediaries (such as APIs, proxies or plugins), no change of data architecture, and no code or SQL syntax change. This remarkable adaptability has made the product a prime mover in the market.
"Vaultree's groundbreaking solution is the first of its kind and will change the encryption landscape as we know it. Data security is not only one of today's hot topics but also the topic of tomorrow. Vaultree is leading the way to a safer future," said Rinki Sethi, member of Vaultree's executive board of directors.
Vaultree's SDK encryption solution tackles the drawbacks of both conventional and contemporary encryption methods with a variety of features, including:
- Close to plaintext processing speed, even at scale
- Keys reside with the client
- End-to-end encrypted in use, decrypted only client-side
- No changes to stack, SQL syntax, data structure, architecture, and network topology
- Complex processing from fulltext search to computations on randomized encrypted data
- Performance and scalability at enterprise levels
- No need for special purpose hardware
Peak performance processing on fully encrypted data enables enterprises to scale to billions of datasets while processing data at speeds similar to unencrypted data processing. Enterprises handling large amounts of sensitive data, including those in financial services, healthcare, pharmaceutical, insurance, retail, telecom, and energy sectors, will be able to mitigate the tremendous economic, cyber, legal, reputational, and business risk of a data breach in plain text — because of the data being encrypted.
"Breaches or leaks will continue happening, no matter how many tools are in the first line of defense, but the second line of defense — encryption — has been neglected for decades because data still has to be decrypted to be worked with. The only way forward is an always-encrypted approach," said Tilo Weigandt, Co-Founder and COO of Vaultree.
Amongst other developments, Vaultree is the first and only (Data-In-Use) encryption solution vendor to partner with Google's AlloyDB for PostgreSQL, leading a new era with a fully functional encryption solution in the cloud. To further expand usage of its revolutionary data protection solution, Vaultree has also partnered with Qrypt. The partnership leverages Qrypt’s ability to independently generate identical symmetric keys at multiple endpoints and quantum-secure future-safe one-time pad encryption paired with Vaultree’s Fully Functional Data-In-Use Encryption to enable fast, future secure data processing in a cloud-first world.
"As it stands, we are the only company globally with the capacity and innovation we have. We are going to grow significantly over the next year enabling organizations with our Data-In-Use encryption technology. We are focusing heavily on bringing this to market fast with our target markets being North America and Europe," said Ryan Lasmaili, Co-Founder and CEO of Vaultree.
About Vaultree
Vaultree has developed the world's first Fully Functional Data-in-Use Encryption solution that solves the industry's fundamental security issue: persistent data encryption, even in the event of a leak. Vaultree enables enterprises, including those in the financial services and healthcare / pharmaceutical sectors, to mitigate the great financial, cyber, legal, reputational, and business risk of a data breach in plain text. With Vaultree, organizations process, search and compute ubiquitous data at scale without ever having to surrender encryption keys or decrypt server-side. If a leak occurs, Vaultree's data-in-use encryption persists, rendering the data unusable to bad actors. Integrating Vaultree into existing database technologies is seamless, requiring no technology or platform changes. Vaultree is a privately held company based in Ireland and the U.S. For more information, please visit www.vaultree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
